CV Sciences Q4 sales fall
Overview
U.S. hemp extracts seller's Q4 sales declined yr/yr due to lower volumes and regulatory challenges
Company posted positive adjusted EBITDA in Q4, driven by reduced operating expenses and higher margins
CV Sciences completed debt restructuring in Q1 2026 to strengthen financial position
Outlook
Company aims to enhance operating efficiency and drive consistent positive cash flow in 2026
CV Sciences sees opportunity to accelerate growth through strategic acquisitions
Company plans to balance near-term profitability with targeted M&A for improved performance
Result Drivers
LOWER SALES VOLUME - Co said Q4 and FY sales decline was driven by temporary out-of-stock issues for key products and restrictive regulations
OPERATING EXPENSES REDUCED - Co attributed improved adjusted EBITDA and reduced operating loss to lower operating expenses
B2B REVENUE - Sequential Q4 sales increase was mostly due to additional B2B revenue
Company press release: ID:nACSrjP8Qa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales |
| $3.31 mln |
|
Q4 Net Income |
| -$206,000 |
|
Q4 Gross Profit |
| $1.67 mln |
|
Q4 Operating Expenses |
| $1.75 mln |
|
Q4 Operating Income |
| -$75,000 |
|
Q4 Pretax Profit |
| -$204,000 |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
